These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 29016929)

  • 21. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
    Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
    EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
    Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
    Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.
    Barish ME; Weng L; Awabdeh D; Zhai Y; Starr R; D'Apuzzo M; Rockne RC; Li H; Badie B; Forman SJ; Brown CE
    Neoplasia; 2022 Aug; 30():100801. PubMed ID: 35550513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
    An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
    Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.
    Zannikou M; Duffy JT; Levine RN; Seblani M; Liu Q; Presser A; Arrieta VA; Chen CJ; Sonabend AM; Horbinski CM; Lee-Chang C; Miska J; Lesniak MS; Gottschalk S; Balyasnikova IV
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36759014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
    Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
    Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
    Kringel R; Lamszus K; Mohme M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells.
    Starr R; Aguilar B; Gumber D; Maker M; Huard S; Wang D; Chang WC; Brito A; Chiu V; Ostberg JR; Badie B; Forman SJ; Alizadeh D; Wang LD; Brown CE
    Cancer Res Commun; 2023 Jan; 3(1):66-79. PubMed ID: 36968221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E; Garaba A; Antonietti S; Ius T; Fontanella MM; Zeppieri M; Panciani PP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.
    Yin Y; Rodriguez JL; Li N; Thokala R; Nasrallah MP; Hu L; Zhang L; Zhang JV; Logun MT; Kainth D; Haddad L; Zhao Y; Wu T; Johns EX; Long Y; Liang H; Qi J; Zhang X; Binder ZA; Lin Z; O'Rourke DM
    Mol Ther; 2022 Jul; 30(7):2537-2553. PubMed ID: 35570396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
    Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
    Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting of the alpha
    Cobb DA; de Rossi J; Liu L; An E; Lee DW
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
    Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
    Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
    Front Immunol; 2020; 11():594271. PubMed ID: 33224149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.